This is a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.
Patients who are 18 years or over of age at time of screening.
Patients who have at least two symptoms with a score of 2 or higher within 72 h from fever onset.
Patients who are diagnosed with dengue by NS1 positive (Phase 2- Part 1 only). And patients who are classified as dengue, zika, influenza, COVID-19 and others (Phase 3- Part 2 only)
Patients who show severe dengue (WHO dengue guideline C, any severe symptoms or clinical laboratory results)
Patients who have previously received dengue vaccine
Patients who have chronic medical conditions such as uncontrolled diabetes mellitus, severe asthma requiring oral steroids or admission to the hospital in the previous 6 months for cardiac disease